Icosavax Reports Positive 12-Month Durability Data for VLP Vaccine Candidate IVX-121
Portfolio Pulse from Benzinga Newsdesk
Icosavax has reported positive 12-month durability data for its VLP vaccine candidate IVX-121. The data from the Phase 1b extension trial in older adults showed persistent GMTs against RSV through day 365. The company also reported a robust immune response against RSV-A in trial participants who were revaccinated with IVX-121 twelve months after the initial dose. The vaccine was generally well tolerated with no additional safety concerns. The company's IVX-A12, a combination of IVX-121 for RSV and IVX-241 for hMPV, is currently in a Phase 2 trial with interim data expected by end 2023.
August 08, 2023 | 9:56 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Icosavax's positive 12-month durability data for its VLP vaccine candidate IVX-121 could potentially boost investor confidence in the company. The ongoing Phase 2 trial of IVX-A12, a combination of IVX-121 and IVX-241, could also be a significant catalyst for the company's stock.
Positive clinical trial results often lead to increased investor confidence, which can drive up a company's stock price. The positive 12-month durability data for IVX-121 and the ongoing Phase 2 trial of IVX-A12 could therefore have a positive impact on Icosavax's stock in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100